The scope of the Committee shall be the development of standardized nomenclature and definitions of terms, test methods, recommended practices, guides, specifications and performance standards for medical and surgical materials and devices. The Committee will encourage research in this field and sponsor symposia, workshops and publications to facilitate the development of such standards. The Committee will promote liaison with other ASTM Committees and other organizations with mutual interests.
6.1 ORGAN ON A CHIP; ORGANS-ON-CHIPS; MICROPHYSIOLOGICAL SYSTEMS; TISSUE-ON-A-CHIP; DRUG DISCOVERY; PATHOPHYSIOLOGY STUDIES; DRUG VALIDATION, DISEASE MODELS; PRECISION MEDICINE; ALTERNATIVES TO ANIMAL MODELS; PHARMACOLOGY TESTING; IN VITRO TESTING; EX VIVO TESTING; PHYSIOLOGY STUDIES; DRUG STUDIES; BIOMEDICAL RESEARCH; DRUG SCREEN; IN VITRO/EX VIVO DRUG SCREENING SYSTEM; IN VITRO/EX VIVO PHYSIOLOGY STUDY SYSTEM; TOXICOLOGY; REGENERATIVE MEDICINE; PATIENT SPECIFIC TESTING; BODY-ON-A CHIP; MULTI-ORGANS ON A CHIP; DRUG DEVELOPMENT; MICROPHSYIOLOGICAL MODEL; BODY ON A CHIP; DISEASE MODELS; CARDIAC
For this field to continue to grow there needs to be consensus on minimum requirements and best practices for cardiac MPS. This will serve to make conversations between different stakeholders easier. Similarly, it will make the science of cardiac MPS more accessible to the larger tissue engineering field. Finally, it will help journals and reviewers aware of the main stakeholders consensus. These things taken together will create safer and more accessible use of cardiac MPS, while simultaneously growing the confidence in the technology and field.
The title and scope are in draft form and are under development within this